Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial | Colorectal Cancer | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal MetastasesA Phase 2 Randomized Clinical Trial

Educational Objective To assess the feasibility and safety of perioperative systemic therapy in patients with resectable colorectal peritoneal metastasis and the response of colorectal peritoneal metastasis to neoadjuvant treatment.
1 Credit CME
Key Points

Question  Is perioperative systemic therapy feasible and safe in patients with resectable colorectal peritoneal metastases?

Findings  In this phase 2 clinical trial analyzing 79 patients randomized to perioperative systemic therapy (experimental arm) or cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone (control arm), the trial arms did not differ significantly regarding the proportions of macroscopic complete cytoreductive surgery (experimental arm, 89%; control arm, 86%) and major postoperative morbidity (experimental arm, 22%; control arm, 33%).

Meaning  Results of this phase 2 trial suggest that perioperative systemic therapy seems feasible and safe in patients diagnosed with resectable colorectal peritoneal metastases, justifying a phase 3 trial.

Abstract

Importance  To date, no randomized clinical trials have investigated perioperative systemic therapy relative to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) alone for resectable colorectal peritoneal metastases (CPM).

Objective  To assess the feasibility and safety of perioperative systemic therapy in patients with resectable CPM and the response of CPM to neoadjuvant treatment.

Design, Setting, and Participants  An open-label, parallel-group phase 2 randomized clinical trial in all 9 Dutch tertiary centers for the surgical treatment of CPM enrolled participants between June 15, 2017, and January 9, 2019. Participants were patients with pathologically proven isolated resectable CPM who did not receive systemic therapy within 6 months before enrollment.

Interventions  Randomization to perioperative systemic therapy or CRS-HIPEC alone. Perioperative systemic therapy comprised either four 3-week neoadjuvant and adjuvant cycles of CAPOX (capecitabine and oxaliplatin), six 2-week neoadjuvant and adjuvant cycles of FOLFOX (fluorouracil, leucovorin, and oxaliplatin), or six 2-week neoadjuvant cycles of FOLFIRI (fluorouracil, leucovorin, and irinotecan) and either four 3-week adjuvant cycles of capecitabine or six 2-week adjuvant cycles of fluorouracil with leucovorin. Bevacizumab was added to the first 3 (CAPOX) or 4 (FOLFOX/FOLFIRI) neoadjuvant cycles.

Main Outcomes and Measures  Proportions of macroscopic complete CRS-HIPEC and Clavien-Dindo grade 3 or higher postoperative morbidity. Key secondary outcomes were centrally assessed rates of objective radiologic and major pathologic response of CPM to neoadjuvant treatment. Analyses were done modified intention-to-treat in patients starting neoadjuvant treatment (experimental arm) or undergoing upfront surgery (control arm).

Results  In 79 patients included in the analysis (43 [54%] men; mean [SD] age, 62 [10] years), experimental (n = 37) and control (n = 42) arms did not differ significantly regarding the proportions of macroscopic complete CRS-HIPEC (33 of 37 [89%] vs 36 of 42 [86%] patients; risk ratio, 1.04; 95% CI, 0.88-1.23; P = .74) and Clavien-Dindo grade 3 or higher postoperative morbidity (8 of 37 [22%] vs 14 of 42 [33%] patients; risk ratio, 0.65; 95% CI, 0.31-1.37; P = .25). No treatment-related deaths occurred. Objective radiologic and major pathologic response rates of CPM to neoadjuvant treatment were 28% (9 of 32 evaluable patients) and 38% (13 of 34 evaluable patients), respectively.

Conclusions and Relevance  In this randomized phase 2 trial in patients diagnosed with resectable CPM, perioperative systemic therapy seemed feasible, safe, and able to induce response of CPM, justifying a phase 3 trial.

Trial Registration  ClinicalTrials.gov Identifier: NCT02758951

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: March 3, 2021.

Published Online: May 19, 2021. doi:10.1001/jamasurg.2021.1642

Corresponding Author: Ignace H. J. T. de Hingh, PhD, Department of Surgery, Catharina Cancer Institute, PO Box 1350, 5602 ZA, Eindhoven, the Netherlands (ignace.d.hingh@catharinaziekenhuis.nl).

Author Contributions: Drs Rovers and de Hingh had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Rovers and Bakkers are co–first authors.

Concept and design: Rovers, Bakkers, Nienhuijs, Burger, Creemers, Thijs, Madsen, van Meerten, Tuynman, Versteeg, Aalbers, Kok, Buffart, Wiezer, Los, Kruijff, de Groot, Witkamp, van Grevenstein, Nederend, Fijneman, Snaebjornsson, Hemmer, Dijkgraaf, Punt, Tanis, de Hingh.

Acquisition, analysis, or interpretation of data: Rovers, Bakkers, Brandt-Kerkhof, Kusters, Aalbers, Boerma, de Reuver, Bremers, Verheul, van Grevenstein, Koopman, Nederend, Lahaye, Kranenburg, van 't Erve, Snaebjornsson, Punt, Tanis, de Hingh.

Drafting of the manuscript: Rovers, Bakkers, Creemers, van 't Erve, de Hingh.

Critical revision of the manuscript for important intellectual content: Nienhuijs, Burger, Thijs, Brandt-Kerkhof, Madsen, van Meerten, Tuynman, Kusters, Versteeg, Aalbers, Kok, Buffart, Wiezer, Boerma, Los, de Reuver, Bremers, Verheul, Kruijff, de Groot, Witkamp, van Grevenstein, Koopman, Nederend, Lahaye, Kranenburg, Fijneman, van 't Erve, Snaebjornsson, Hemmer, Dijkgraaf, Punt, Tanis.

Statistical analysis: Rovers, Bakkers, van 't Erve, Dijkgraaf.

Administrative, technical, or material support: Burger, Kusters, Bremers, Nederend, van 't Erve, Snaebjornsson.

Supervision: Brandt-Kerkhof, Tuynman, Kusters, Aalbers, Wiezer, Boerma, Bremers, Verheul, Lahaye, Dijkgraaf, Punt, Tanis, de Hingh.

Conflict of Interest Disclosures: Dr Koopman reported serving as a paid advisor for Nordic Farma Merck-Serono, Pierre Fabre, and Servier, and receiving institutional scientific grants from Bayer, Bristol Myers Squibb, Merck, Roche, and Servier outside the submitted work. Dr Punt reported serving as a paid advisor for Nordic Pharma and Servier. Dr Tanis reported receiving unrestricted research grants from Allergan (LifeCell) outside the submitted work. Dr de Hingh reported receiving grants from Roche, QP&S, and RanD Biotech outside the submitted work. No other disclosures were reported.

Funding/Support: This work was funded by Dutch Cancer Society grant 10795 and F. Hoffmann-La Roche grant ML39718.

Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: The members of the Dutch Peritoneal Oncology Group and the Dutch Colorectal Cancer Group appear in Supplement 4.

Meeting Presentation: The present work was presented at the virtual European Society for Medical Oncology (ESMO) World Conference on Gastrointestinal Cancer; July 3, 2020; https://esmoworldgivirtual2020.com/.

Data Sharing Statement: See Supplement 3.

Additional Contributions: The Netherlands Comprehensive Cancer Organization provided data management and trial monitoring.

References
1.
Evrard  S .  Autopsy of an expert consensus: end of hyperthermic intraperitoneal chemotherapy in colorectal carcinomatosis.   Eur J Surg Oncol. 2018;44(12):1845-1846. doi:10.1016/j.ejso.2018.07.061 PubMedGoogle ScholarCrossref
2.
Ceelen  W .  HIPEC with oxaliplatin for colorectal peritoneal metastasis: the end of the road?   Eur J Surg Oncol. 2019;45(3):400-402. doi:10.1016/j.ejso.2018.10.542 PubMedGoogle ScholarCrossref
3.
Klaver  CEL , Groenen  H , Morton  DG , Laurberg  S , Bemelman  WA , Tanis  PJ ; research committee of the European Society of Coloproctology.  Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines.   Colorectal Dis. 2017;19(3):224-236. doi:10.1111/codi.13593 PubMedGoogle ScholarCrossref
4.
Eveno  C , Passot  G , Goéré  D ,  et al.  Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.   Ann Surg Oncol. 2014;21(6):1792-1800. doi:10.1245/s10434-013-3442-3 PubMedGoogle ScholarCrossref
5.
Franko  J , Shi  Q , Meyers  JP ,  et al; Analysis and Research in Cancers of the Digestive System (ARCAD) Group.  Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.   Lancet Oncol. 2016;17(12):1709-1719. doi:10.1016/S1470-2045(16)30500-9 PubMedGoogle ScholarCrossref
6.
Rovers  KP , Simkens  GA , Punt  CJ , van Dieren  S , Tanis  PJ , de Hingh  IH .  Perioperative systemic therapy for resectable colorectal peritoneal metastases: sufficient evidence for its widespread use? a critical systematic review.   Crit Rev Oncol Hematol. 2017;114:53-62. doi:10.1016/j.critrevonc.2017.03.028 PubMedGoogle ScholarCrossref
7.
Chicago Consensus Working Group.  The Chicago consensus on peritoneal surface malignancies: management of colorectal metastases.   Ann Surg Oncol. 2020;27(6):1761-1767. doi:10.1245/s10434-020-08315-x PubMedGoogle ScholarCrossref
8.
Bushati  M , Rovers  KP , Sommariva  A ,  et al.  The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).   Eur J Surg Oncol. 2018;44(12):1942-1948. doi:10.1016/j.ejso.2018.07.003 PubMedGoogle ScholarCrossref
9.
Rovers  KP , Bakkers  C , van Erning  FN ,  et al.  Adjuvant systemic chemotherapy vs active surveillance following up-front resection of isolated synchronous colorectal peritoneal metastases.   JAMA Oncol. 2020;6(8):e202701. doi:10.1001/jamaoncol.2020.2701 PubMedGoogle Scholar
10.
Dutch Colorectal Cancer Group. CAIRO 6. Accessed December 1, 2020. https://dccg.nl/trial/cairo-6
11.
Rovers  KP , Bakkers  C , Simkens  GAAM ,  et al; Dutch Peritoneal Oncology Group (DPOG); Dutch Colorectal Cancer Group (DCCG).  Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).   BMC Cancer. 2019;19(1):390. doi:10.1186/s12885-019-5545-0 PubMedGoogle ScholarCrossref
12.
Jacquet  P , Sugarbaker  PH .  Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.   Cancer Treat Res. 1996;82:359-374. doi:10.1007/978-1-4613-1247-5_23 PubMedGoogle ScholarCrossref
13.
Hompes  D , Ruers  T .  Review: incidence and clinical significance of bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer.   Eur J Surg Oncol. 2011;37(9):737-746. doi:10.1016/j.ejso.2011.06.004 PubMedGoogle ScholarCrossref
14.
Schmoll  HJ , Van Cutsem  E , Stein  A ,  et al.  ESMO Consensus guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.   Ann Oncol. 2012;23(10):2479-2516. doi:10.1093/annonc/mds236 PubMedGoogle ScholarCrossref
15.
Kuijpers  AMJ , Mirck  B , Aalbers  AGJ ,  et al.  Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol.   Ann Surg Oncol. 2013;20(13):4224-4230. doi:10.1245/s10434-013-3145-9 PubMedGoogle ScholarCrossref
16.
Verwaal  VJ , Bruin  S , Boot  H , van Slooten  G , van Tinteren  H .  8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.   Ann Surg Oncol. 2008;15(9):2426-2432. doi:10.1245/s10434-008-9966-2 PubMedGoogle ScholarCrossref
17.
Wisselink  DD , Braakhuis  LLF , Gallo  G ,  et al.  Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.   Crit Rev Oncol Hematol. 2019;142:119-129. doi:10.1016/j.critrevonc.2019.06.014 PubMedGoogle ScholarCrossref
18.
Dindo  D , Demartines  N , Clavien  PA .  Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.   Ann Surg. 2004;240(2):205-213. doi:10.1097/01.sla.0000133083.54934.ae PubMedGoogle ScholarCrossref
19.
Eisenhauer  EA , Therasse  P , Bogaerts  J ,  et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).   Eur J Cancer. 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026 PubMedGoogle ScholarCrossref
20.
Mandard  AM , Dalibard  F , Mandard  JC ,  et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations.   Cancer. 1994;73(11):2680-2686. doi:10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C PubMedGoogle ScholarCrossref
21.
Solass  W , Sempoux  C , Detlefsen  S , Carr  NJ , Bibeau  F .  Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS).   Pleura Peritoneum. 2016;1(2):99-107. doi:10.1515/pp-2016-0011 PubMedGoogle ScholarCrossref
22.
Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Updated June 14, 2010. Accessed December 1, 2020. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
23.
Leimkühler  M , Hemmer  PHJ , Reyners  AKL ,  et al.  Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study.   World J Surg Oncol. 2019;17(1):14. doi:10.1186/s12957-018-1554-8 PubMedGoogle ScholarCrossref
24.
Glockzin  G , Zeman  F , Croner  RS ,  et al.  Perioperative systemic chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastasis: results of the prospective multicenter phase 2 COMBATAC trial.   Clin Colorectal Cancer. 2018;17(4):285-296. doi:10.1016/j.clcc.2018.07.011 PubMedGoogle ScholarCrossref
25.
Grothey  A , Sobrero  AF , Shields  AF ,  et al.  Duration of adjuvant chemotherapy for stage III colon cancer.   N Engl J Med. 2018;378(13):1177-1188. doi:10.1056/NEJMoa1713709 PubMedGoogle ScholarCrossref
26.
Passot  G , Vaudoyer  D , Cotte  E ,  et al.  Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis.   Ann Surg. 2012;256(1):125-129. doi:10.1097/SLA.0b013e318255486a PubMedGoogle ScholarCrossref
27.
Passot  G , You  B , Boschetti  G ,  et al.  Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis.   Ann Surg Oncol. 2014;21(8):2608-2614. doi:10.1245/s10434-014-3647-0 PubMedGoogle ScholarCrossref
28.
Klinger  M , Tamandl  D , Eipeldauer  S ,  et al.  Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.   Ann Surg Oncol. 2010;17(8):2059-2065. doi:10.1245/s10434-010-0972-9 PubMedGoogle ScholarCrossref
29.
Beal  EW , Suarez-Kelly  LP , Kimbrough  CW ,  et al.  Impact of neoadjuvant chemotherapy on the outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a multi-institutional retrospective review.   J Clin Med. 2020;9(3):748. doi:10.3390/jcm9030748 PubMedGoogle ScholarCrossref
30.
Hallam  S , Tyler  R , Price  M , Beggs  A , Youssef  H .  Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy.   BJS Open. 2019;3(5):585-594. doi:10.1002/bjs5.50179 PubMedGoogle ScholarCrossref
31.
Quénet  F , Elias  D , Roca  L ,  et al; UNICANCER-GI Group and BIG Renape Group.  Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.   Lancet Oncol. 2021;22(2):256-266. doi:10.1016/S1470-2045(20)30599-4 PubMedGoogle ScholarCrossref
32.
Hentzen  JEKR , Constansia  RDN , Been  LB ,  et al.  Diagnostic laparoscopy as a selection tool for patients with colorectal peritoneal metastases to prevent a non-therapeutic laparotomy during cytoreductive surgery.   Ann Surg Oncol. 2020;27(4):1084-1093. doi:10.1245/s10434-019-07957-w PubMedGoogle ScholarCrossref
33.
van Oudheusden  TR , Braam  HJ , Luyer  MDP ,  et al.  Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.   Ann Surg Oncol. 2015;22(4):1236-1242. doi:10.1245/s10434-014-4148-x PubMedGoogle ScholarCrossref
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close